DE60041147D1 - Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen - Google Patents

Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen

Info

Publication number
DE60041147D1
DE60041147D1 DE60041147T DE60041147T DE60041147D1 DE 60041147 D1 DE60041147 D1 DE 60041147D1 DE 60041147 T DE60041147 T DE 60041147T DE 60041147 T DE60041147 T DE 60041147T DE 60041147 D1 DE60041147 D1 DE 60041147D1
Authority
DE
Germany
Prior art keywords
alendronate
treatment
calcitriol
pharmaceutical composition
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60041147T
Other languages
English (en)
Inventor
Sung An Kang
Kyung Hee Lee
Chung Shil Kwak
Chang Jong Kim
Yong Oh Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YUYU PHARMA Inc
Original Assignee
YUYU PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19616174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60041147(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by YUYU PHARMA Inc filed Critical YUYU PHARMA Inc
Application granted granted Critical
Publication of DE60041147D1 publication Critical patent/DE60041147D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60041147T 1999-10-20 2000-10-20 Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen Expired - Lifetime DE60041147D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019990045623A KR100317935B1 (ko) 1999-10-20 1999-10-20 대사성 골질환 치료용 약제조성물 및 이의 제조방법
PCT/KR2000/001188 WO2001028564A1 (en) 1999-10-20 2000-10-20 Pharmaceutical compositions and preparations for treatment of metabolic bone disease

Publications (1)

Publication Number Publication Date
DE60041147D1 true DE60041147D1 (de) 2009-01-29

Family

ID=19616174

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60041147T Expired - Lifetime DE60041147D1 (de) 1999-10-20 2000-10-20 Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen

Country Status (10)

Country Link
US (1) US6835722B1 (de)
EP (1) EP1229917B1 (de)
JP (1) JP4875818B2 (de)
KR (1) KR100317935B1 (de)
CN (1) CN100577172C (de)
AT (1) ATE417615T1 (de)
AU (1) AU1059601A (de)
DE (1) DE60041147D1 (de)
ES (1) ES2316392T3 (de)
WO (1) WO2001028564A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
JP2004528365A (ja) * 2001-05-02 2004-09-16 ノバルティス アクチエンゲゼルシャフト 骨再吸収症および骨粗しょう症の処置または予防におけるビスホスホネートの吸入投与方法
CA2454200A1 (en) * 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20050026871A1 (en) * 2002-07-17 2005-02-03 Moshe Flashner-Barak Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
AU2003300984A1 (en) * 2002-12-16 2004-07-22 Teva Pharmaceutical Industries Ltd. Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
DE20321698U1 (de) 2002-12-16 2008-12-24 Teva Pharmaceutical Industries Ltd. Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
EP1680092A2 (de) * 2003-09-29 2006-07-19 Cipla Ltd. Pharmazeutische formulierung mit verbesserter haltbarkeit
JP2007523184A (ja) 2004-02-19 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド ラロキシフェン及びアレンドロネートの組合せを用いての改良された療法
FR2871699A1 (fr) * 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
WO2006046100A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Pharmaceutical composition of alendronic acid
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
PT1734251E (pt) * 2005-06-17 2007-03-30 Magneti Marelli Powertrain Spa Injector de combustível
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
US20080076742A1 (en) * 2005-10-31 2008-03-27 Wisconsin Alumni Research Foundation Methods and compositions for treating diseases associated with neovascualrization
CN101541347B (zh) * 2006-08-02 2012-10-31 内布拉斯加大学评议会 药物载体、其合成及其使用方法
KR100822133B1 (ko) * 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
US7964584B2 (en) 2008-08-01 2011-06-21 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
CA2732863A1 (en) * 2008-08-01 2010-02-04 Dong Wha Pharmaceutical Co., Ltd. A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt
EP2201937A1 (de) * 2008-12-23 2010-06-30 Teva Pharmaceutical Industries Ltd. Formulierungen enthaltend Vtamin Doder ein Derivativ davon
WO2011024208A1 (en) * 2009-08-24 2011-03-03 Colotech A/S Combination dosage form with acetylsalicylic acid, calcitriol and calcium
KR101102364B1 (ko) 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
CN102210697B (zh) * 2010-04-02 2013-05-22 秦引林 用于治疗代谢性骨病的药物组合
CN102210696A (zh) * 2010-04-02 2011-10-12 秦引林 一种含唑来膦酸的药物组合
EP2468265A3 (de) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogene Zubereitungen mit Vitamin D
CN103202848A (zh) * 2013-03-21 2013-07-17 青岛正大海尔制药有限公司 用于治疗骨质疏松的药物组合物
PT106978A (pt) 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d
KR101983654B1 (ko) * 2018-07-24 2019-05-29 한국과학기술원 Cfc 증후군 환자의 발달 저해를 완화할 수 있는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR884628A (fr) 1942-03-25 1943-08-23 Cie Ingersoll Rand Procédé de bourrage des trous de mines et appareil pour sa mise en oeuvre
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
JPH05124966A (ja) * 1991-10-31 1993-05-21 Doujin Iyaku Kako Kk カルシトリオール固形製剤
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
JP3566984B2 (ja) * 1994-06-02 2004-09-15 帝人株式会社 骨形成促進剤
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
KR19980702210A (ko) * 1995-02-17 1998-07-15 폴락 돈나 엘 비척추골 골절의 위험률을 감소시키는 방법
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
US5952317A (en) * 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
EP1021401A1 (de) * 1995-09-21 2000-07-26 Wisconsin Alumni Research Foundation Calcitriol derivate und ihre verwendungen
JPH1160489A (ja) * 1997-06-12 1999-03-02 Teijin Ltd 骨粗鬆症予防剤または治療剤
US6410782B1 (en) * 1997-07-09 2002-06-25 Geange Ltd. Diphosphonic acid salts for the treatment of osteoporosis
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법

Also Published As

Publication number Publication date
EP1229917A4 (de) 2005-08-03
JP4875818B2 (ja) 2012-02-15
ATE417615T1 (de) 2009-01-15
KR20010037885A (ko) 2001-05-15
WO2001028564A1 (en) 2001-04-26
KR100317935B1 (ko) 2001-12-22
EP1229917A1 (de) 2002-08-14
JP2003514776A (ja) 2003-04-22
AU1059601A (en) 2001-04-30
ES2316392T3 (es) 2009-04-16
CN100577172C (zh) 2010-01-06
US6835722B1 (en) 2004-12-28
CN1420777A (zh) 2003-05-28
EP1229917B1 (de) 2008-12-17

Similar Documents

Publication Publication Date Title
DE60041147D1 (de) Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen
MXPA04012998A (es) Modulares de receptores nucleares de hormonas esteroideas triciclicos.
US10143685B2 (en) Parenteral and topical compositions for pain
CA2151240A1 (en) Biophosphonate/estrogen therapy for treating and preventing bone loss
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
ATE289199T1 (de) Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
MXPA05007857A (es) Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
CA2457840A1 (en) Hdl for the treatment of stroke and other ischemic conditions
CA2294101A1 (en) A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
MX2007000967A (es) Composiciones de risedronato y metodos para su uso.
DE60043346D1 (de) Methoden zur hemmung der aktivität der osteoklasten
KR970061249A (ko) 골다공증을 치료 또는 방지하기 위한 조성물
RU2007117492A (ru) Применение органических соединений
US6399592B1 (en) Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
PL371264A1 (en) Method for the treatment of bone disorders
MX2013010622A (es) Composiciones y métodos para el tratamiento de enfermedades y transtornos relacionados con el tejido musculoesquelético utilizando complejos de análogo de citrato de ion metálico.
JPH061721A (ja) 疼痛処置剤、及び疼痛軽減作用増強剤
JP2003095974A (ja) 骨形成を安全に促進させる医薬複合剤
WO2005074944A1 (en) Use of sodium neridronate to promote new bone formation
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
CN117298111A (zh) 一种酰胺类化合物在制备治疗骨质疏松药物中的应用
AU2006311227B2 (en) Use of clodronic acid for the treatment of navicular syndrome

Legal Events

Date Code Title Description
8364 No opposition during term of opposition